Recombinant Vaccine Confers More Protection Against Influenza

THURSDAY, Dec. 14, 2023 -- A high-dose recombinant influenza vaccine is more effective than standard-dose vaccine among adults aged 50 to 64 years, according to a study published in the Dec. 14 issue of the New England Journal of Medicine. Amber...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news